Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pt(0506)101
- Development stage
- Unknown
- Lead developer
- Beijing Fengshuo Weikang Technology Development
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Pt(0506)101 is a novel platinum-based antineoplastic small molecule developed by Beijing Shuobai Pharmaceutical Technology. As a platinum complex, it is designed to exert cytotoxic effects by covalently binding to DNA, primarily forming intra-strand and inter-strand cross-links. These structural modifications distort the DNA helix, effectively blocking DNA replication and RNA transcription, which triggers cell cycle arrest and programmed cell death (apoptosis). Pt(0506)101 is currently in Phase Ib/IIa clinical development in China, where it is being evaluated as a first-line treatment for patients with unresectable locally advanced, recurrent, or metastatic HER2-negative, PD-L1-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma in combination with capecitabine and the PD-1 inhibitor sintilimab.
- Other names
- Pt(0506)101
02
Targets
DNABAX (Apoptosis regulator BAX)
Beyond the preview
Go deeper on Pt(0506)101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pt(0506)101.